Debate: Follow the Bleeding Risk, Shorten DAPT!
We Recommend
Disclosures
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:
- Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Amgen, Arena, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Deerfield, Daiichi-Sankyo, Eli Lilly, Haemonetics, Idorsia, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company
- Grant Support/Research Contract (Institutional) - Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions